Journal article
A phase II study of oral clofazimine in unresectable and metastatic hepatocellular carcinoma
Abstract
BACKGROUND: Hepatocellular carcinoma is highly refractory to most chemotherapeutic agents. Clofazimine, a riminophenazine compound used to treat leprosy since 1962, inhibits various cancer cell lines, including hepatocellular carcinoma cell lines, via phospholipase A2 dependant processes. Clofazimine also inhibits p170-glycoprotein, the mdr1 gene product.
PATIENTS AND METHODS: Thirty patients (26 males and four females) with unresectable (25) …
Authors
Ruff P; Chasen MR; Long JEH; van Rensburg CEJ
Journal
Annals of Oncology, Vol. 9, No. 2, pp. 217–219
Publisher
Elsevier
Publication Date
February 1998
DOI
10.1023/a:1008204911774
ISSN
0923-7534